Clinical Trial Update: Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus) [Phase 3]

View source ↗

Summary

A Phase 3 trial compared D961H 20 mg twice daily versus 20 mg once daily in patients with refractory reflux esophagitis; the study completed and results were po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Reflux Esophagitis

Drugs mentioned

• D961H

Snippet

Sponsor: AstraZeneca | Conditions: Refractory Reflux Esophagitis | Phase 3 | Status: COMPLETED | Results posted: 2015-08-14